ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $140,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Eric Karas sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares in the company, valued at approximately $107,744. The trade was a 56.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

ARS Pharmaceuticals Price Performance

NASDAQ:SPRY opened at $12.36 on Friday. ARS Pharmaceuticals, Inc. has a 1 year low of $7.55 and a 1 year high of $18.51. The company has a market cap of $1.20 billion, a P/E ratio of -24.24 and a beta of 1.03. The stock’s fifty day moving average price is $12.06 and its two-hundred day moving average price is $13.05.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.56. The business had revenue of $86.58 million during the quarter, compared to analysts’ expectations of $15.46 million. On average, analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SPRY. Oppenheimer began coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective on the stock. Leerink Partners increased their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Scotiabank assumed coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price on the stock. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Raymond James increased their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $31.00.

Institutional Investors Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Bernard Wealth Management Corp. purchased a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $27,000. KLP Kapitalforvaltning AS purchased a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $73,000. BNP Paribas Financial Markets purchased a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth $75,000. Ball & Co Wealth Management Inc. bought a new position in ARS Pharmaceuticals in the fourth quarter valued at $105,000. Finally, Compass Capital Corp MA ADV bought a new position in ARS Pharmaceuticals in the fourth quarter valued at $106,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.